To assess the potential therapeutic value of targeting WEE1 and CHK1 in prostate cancer, we first evaluated WEE1 and CHK1 expression in a panel of prostate cancer cell lines with different genetic backgrounds. This evidence concerns the gene CHEK1 and prostate carcinoma.